[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cg Oncology Inc (CGON)

Cg Oncology Inc (CGON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,133,127
  • Shares Outstanding, K 88,202
  • Annual Sales, $ 4,040 K
  • Annual Income, $ -161,000 K
  • EBIT $ -215 M
  • EBITDA $ -215 M
  • 60-Month Beta 0.41
  • Price/Sales 1,615.58
  • Price/Cash Flow N/A
  • Price/Book 5.97

Options Overview Details

View History
  • Implied Volatility 111.63% (-3.58%)
  • Historical Volatility 46.99%
  • IV Percentile 98%
  • IV Rank 94.43%
  • IV High 115.21% on 05/14/26
  • IV Low 50.89% on 08/18/25
  • Expected Move (DTE 34) 14.54 (21.72%)
  • Put/Call Vol Ratio 0.27
  • Today's Volume 117
  • Volume Avg (30-Day) 1,209
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 50,268
  • Open Int (30-Day) 49,208
  • Expected Range 52.40 to 81.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.70
  • Number of Estimates 6
  • High Estimate $-0.67
  • Low Estimate $-0.73
  • Prior Year $-0.54
  • Growth Rate Est. (year over year) -29.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.03 +6.19%
on 04/16/26
75.50 -11.35%
on 05/14/26
-0.75 (-1.11%)
since 04/15/26
3-Month
50.50 +32.53%
on 02/17/26
75.50 -11.35%
on 05/14/26
+15.43 (+29.96%)
since 02/13/26
52-Week
23.65 +183.00%
on 08/11/25
75.50 -11.35%
on 05/14/26
+41.58 (+164.02%)
since 05/15/25

Most Recent Stories

More News
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat...

CGON : 66.93 (-3.75%)
CGON's Billion-Dollar Cash Pile Masking the Absence of a Commercial Product

Barchart Research What to Expect from CGON Earnings CGON Generated May 11, 2026 Current Price $69.32 EPS Estimate $$-0.60 Consensus Rating Strong Buy Average Move 5.32% CGON's Billion-Dollar Cash Pile...

CGON : 66.93 (-3.75%)
CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

- First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented - - Visit CG Oncology at booth...

CGON : 66.93 (-3.75%)
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026  PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant...

CGON : 66.93 (-3.75%)
CG Oncology to Present at Upcoming Investor Conferences in May

DALLAS, May 05, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer,...

CGON : 66.93 (-3.75%)
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates

PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026 CORE-008 Cohort CX Phase 2 first results of combination...

CGON : 66.93 (-3.75%)
CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference

IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating...

CGON : 66.93 (-3.75%)
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced...

ONCY : 0.8500 (-2.62%)
CGON : 66.93 (-3.75%)
TAK : 16.61 (-0.12%)
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC

- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial...

CGON : 66.93 (-3.75%)
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

IRVINE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing...

CGON : 66.93 (-3.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology is based in IRVINE, Calif.

See More

Key Turning Points

3rd Resistance Point 72.66
2nd Resistance Point 71.33
1st Resistance Point 69.13
Last Price 66.93
1st Support Level 65.60
2nd Support Level 64.27
3rd Support Level 62.07

See More

52-Week High 75.50
Last Price 66.93
Fibonacci 61.8% 55.69
Fibonacci 50% 49.58
Fibonacci 38.2% 43.46
52-Week Low 23.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.